A Rare Case of Factor XIII Deficiency in the Setting of Cancer Immunotherapy
| Autor: | Khashayar Farzam |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
pulmonary embolism medicine.medical_treatment Cardiology Pembrolizumab 030204 cardiovascular system & hematology Gastroenterology Tissue plasminogen activator factor xiii deficiency mechanical thrombectomy 03 medical and health sciences 0302 clinical medicine Cancer immunotherapy Internal medicine Internal Medicine medicine Factor XIII deficiency bleeding disorder business.industry factor xiii massive pulmonary embolism General Engineering Hematology Factor XIII medicine.disease Pulmonary embolism Mechanical thrombectomy Cryoprecipitate pembrolizumab business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.15299 |
| Popis: | Factor XIII deficiency is a rare bleeding disorder, which may be congenital or acquired, and is most commonly diagnosed in early childhood. It has a prevalence that is as low as one in 5,000,000. Acquired factor XIII deficiency is considered to be a more rare form, with less than 100 cases reported in the literature. This disorder can be clinically characterized by recurrent and severe unexplained bleeding. This case describes a patient with no prior bleeding disorders, who suffered from recurrent bleeding episodes while being treated with cancer immunotherapy, specifically pembrolizumab, and was subsequently diagnosed with factor XIII deficiency. She required cryoprecipitate infusion due to the persistent bleeding and subsequently developed saddle pulmonary embolism. The patient was not a candidate for tissue plasminogen activator (tPA) due to her recurrent bleeding and required mechanical thrombectomy. Given the timeline of symptoms, the patient likely developed acquired factor XIII deficiency due to her cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|